Le Lézard
Classified in: Health
Subject: SVY

United States (Platelet Rich Plasma) and Stem Cell Alopecia Treatment Market 2013-2018 & 2018-2025: Rise In Disease Awareness, Increased Treatment Rate, & Growing Adoption Of Novel Treatment Therapies


DUBLIN, Nov. 16, 2018 /PRNewswire/ --

The "U.S. PRP (Platelet Rich Plasma) and Stem Cell Alopecia Treatment Market Size, Share & Trends Analysis Report By Treatment, By End User (Dermatology Clinics, Hospitals), And Segment Forecasts, 2018 - 2025" report has been added to ResearchAndMarkets.com's offering.

Research and Markets Logo

The U.S. PRP and stem cell alopecia treatment market size is expected to reach USD 183.3 million by 2025 at a 5.1% CAGR during the forecast period.

Factors contributing to the growth of this market include rise in disease awareness, increased treatment rate, and growing adoption of novel treatment therapies providing positive patient outcome. Moreover, lower incidences of negative side effects due to this therapy is anticipated to fuel demand for platelet rich plasma (PRP) and stem cell therapy.

Adoption of PRP and stem cell therapy for alopecia is expected to increase owing to rise in number of patients preferring novel therapies over conventional therapies. In addition to this, shorter treatment duration, faster hair regrowth, and improved patient outcome are expected to drive demand for these therapies over the forecast period.

By treatment type, PRP procedures accounted for the largest share of 58.1% in 2017 in terms of procedural volume. However, owing to lower prices of PRP procedures, stem cell therapy procedures accounted for the dominant revenue share in 2017, valued at USD 70.1 million. By end use, the dermatology clinics segment accounted for 85.0% of the total market revenue in 2017, owing to its lower therapy cost as compared to hospitals.

The competitive landscape includes clinics such as Orange County Hair Restoration Center, Hair Sciences Center of Colorado, Evolution Hair Loss Institute, Savola Aesthetic Dermatology Center, PLC, NovaGenix, Virginia Surgical Center, and Hair Transplant Institute of Miami.

Further key findings from the report suggest:

Key Topics Covered:

Chapter 1 Research Methodology

Chapter 2 Executive Summary

Chapter 3 Market Variables, Trends & Scope
3.1 Market Segmentation & Scope
3.1.1 Market driver analysis
3.1.1.1 Novel therapies leading to efficacious treatment and improved patient outcomes
3.1.2 Market restraint analysis
3.1.2.1 Lack of reimbursement for PRP and stem cell therapies in the U.S.
3.1.2.2 Availability of other alternative cosmetic products used for enhancing aesthetics
3.2 U.S. PRP and stem cell alopecia treatment market - PESTEL Analysis
3.3 Industry Analysis - Porter's
3.4 PRP & Stem Cell Therapy Procedures Performed In the U.S., 2016 & 2017

Chapter 4 U.S. PRP and Stem Cell Alopecia Treatment Market: Treatment Estimates & Trend Analysis 2013-2025
4.1 Market: By treatment movement analysis
4.2 Platelet Rich Plasma (PRP) Injections
4.3 Stem Cell Therapy

Chapter 5 U.S. PRP and Stem Cell Alopecia Treatment Market: End-User Estimates & Trend Analysis
5.1 Market: By end - user movement analysis
5.2 Hospitals
5.3 Dermatology Clinics
5.4 Others

Chapter 6 Competitive Landscape

For more information about this report visit https://www.researchandmarkets.com/research/p3chzv/united_states?w=5

Did you know that we also offer Custom Research? Visit our Custom Research page to learn more and schedule a meeting with our Custom Research Manager.

Media Contact:

Laura Wood, Senior Manager
[email protected]  

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

SOURCE Research and Markets


These press releases may also interest you

at 08:20
Parse Biosciences, a leading provider of accessible and scalable single cell sequencing solutions, today announced it has launched its Laboratory Automation Provider Program, enabling automation providers to readily support the adoption of Parse's...

at 08:15
Seed Health, a microbiome science company, today announced the appointment of Zain Kassam, M.D., M.P.H., as Chief Medical Officer. An award-winning physician-scientist, Dr. Kassam has played a pivotal role in the advancement of microbiome science for...

at 08:10
bioAffinity Technologies, Inc. , a biotechnology company focused on the need for noninvasive, accurate tests for the detection of early-stage lung cancer and other lung diseases, today announced David Elzi, Ph.D., has been named Vice President of...

at 08:10
Amneal Pharmaceuticals, Inc. ("Amneal" or the "Company") today announced the availability of Over the Counter ("OTC") Naloxone Hydrochloride (Naloxone HCI) Nasal Spray, USP, 4mg, following Abbreviated New Drug Application ("ANDA") approval from the...

at 08:10
BigHat Biosciences, a biotechnology company with an artificial intelligence/machine learning-guided antibody discovery and development platform announced a collaboration with Janssen Biotech Inc., a Johnson & Johnson company. This strategic...

at 08:10
Kiromic BioPharma, Inc. ("Kiromic" or the "Company") announces consistent favorable safety, tolerability, and efficacy from follow-up visits of the first cohort of three patients enrolled in the Company's Deltacel-01 Phase 1 clinical trial....



News published on and distributed by: